Unknown

Dataset Information

0

Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.


ABSTRACT: Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosylating enzymes and play important roles in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, a poly-ADP-ribose transferase, and suffer from poor selectivity. PARP16, a mono-ADP-ribose transferase, has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Here we newly characterized epigallocatechin-3-gallate (EGCG) as a potential inhibitor of PARP16. We found that EGCG was associated with PARP16 and dramatically inhibited its activity in vitro. Moreover, EGCG suppressed the ER stress-induced phosphorylation of PERK and the transcription of unfolded protein response-related genes, leading to dramatically increase of cancer cells apoptosis under ER stress conditions, which was dependent on PARP16. These findings newly characterized EGCG as a potential inhibitor of PARP16, which can enhance the ER stress-induced cancer cell apoptosis, suggesting that a combination of EGCG and ER stress-induced agents might represent a novel approach for cancer therapy or chemoprevention.

SUBMITTER: Wang J 

PROVIDER: S-EPMC5502302 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.

Wang Juanjuan J   Zhu Chenggang C   Song Dan D   Xia Ruiqi R   Yu Wenbo W   Dang Yongjun Y   Fei Yiyan Y   Yu Long L   Wu Jiaxue J  

Cell death discovery 20170710


Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosylating enzymes and play important roles in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, a poly-ADP-ribose transferase, and suffer from poor selectivity. PARP16, a mono-ADP-ribose transferase, has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Here we newly characterized epigallocatechin-3-gallate (EGCG) as a potential inhibit  ...[more]

Similar Datasets

| S-EPMC3244823 | biostudies-literature
| S-EPMC5346735 | biostudies-literature
2024-07-17 | GSE208144 | GEO
| S-EPMC8397540 | biostudies-literature
| S-EPMC4250062 | biostudies-literature
| S-EPMC4554544 | biostudies-literature
| S-EPMC4826942 | biostudies-literature